• Topics

  • Formats

Published 31 August 2026

Author(s): Alice Vanneste, Axelle Jankelevitch, Linda Lukeba, Peter Sinnaeve, Isabelle Huys, & Tom Adriaenssens 

Patient experience data (PED) are increasingly recognised as a methodological and strategic innovation in drug development, yet their implementation in clinical trial design remains inconsistent. Drawing on a structured literature review and multi-stakeholder interviews, this analysis examines how PED inform endpoint decision-making. Although clinical development is shifting towards more patient-informed measures, challenges persist due to limited standardisation, validation, methodological gaps and operational constraints. Opportunities include early patient involvement, validated disease-specific measures, consensus-based core outcome sets and clearer regulatory guidance, enabling meaningful and structured PED implementation that strengthens evidence generation, reduces development risk and improves trial efficiency and real-world relevance.

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?